The efficacy and safety of sirolimus in immunosuppression after liver transplantation
10.3760/cma.j.issn.0254-1785.2009.07.011
- VernacularTitle:西罗莫司在肝移植术后免疫抑制中的效果及安全性
- Author:
Haibin ZHANG
;
Yong FU
;
Ning YANG
;
Xin ZHANG
;
Guangshun YANG
- Publication Type:Journal Article
- Keywords:
Liver transplantation;
Sirolimus;
Tacrolimus
- From:
Chinese Journal of Organ Transplantation
2009;30(7):428-430
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo evaluate the efficacy and safety of Sirolimus (SRL) in immunosuppression following liver transplantation. Methods SRL was applied in 21 patients totally.Indication for adoption was Tac-related nephrotoxicity (4/21), suspiciously Tac-related hepatoxicity (8/21), Tac overdose (3/21), renal insufficiency pre-operation (2/21), or cancer (4/21). Median follow-up was 25. 4 months. Results SRL provided an adequate prophylaxis against rejection in all study patients, with one case of acute rejection. Sirolimus was Withdrawn in 2 cases due to its sideeffect. Tat-induced hepatoxicity in 6 cases and nephrotoxicity in 3 cases were relieved significantly.Conclusions SRL given alone appears to be an effective primary immunosuppressant regimen fororthotopic liver transplantation patients. Early conversion contributes to significant improvement of Tac-related hepatoxicity and nephrotoxicity.
